Your browser doesn't support javascript.
loading
A MicroRNA Next-Generation-Sequencing Discovery Assay (miND) for Genome-Scale Analysis and Absolute Quantitation of Circulating MicroRNA Biomarkers.
Khamina, Kseniya; Diendorfer, Andreas B; Skalicky, Susanna; Weigl, Moritz; Pultar, Marianne; Krammer, Teresa L; Fournier, Catharine Aquino; Schofield, Amy L; Otto, Carolin; Smith, Aaron Thomas; Buchtele, Nina; Schoergenhofer, Christian; Jilma, Bernd; Frank, Bernhard J H; Hofstaetter, Jochen G; Grillari, Regina; Grillari, Johannes; Ruprecht, Klemens; Goldring, Christopher E; Rehrauer, Hubert; Glaab, Warren E; Hackl, Matthias.
Afiliação
  • Khamina K; TAmiRNA GmbH, 1110 Vienna, Austria.
  • Diendorfer AB; TAmiRNA GmbH, 1110 Vienna, Austria.
  • Skalicky S; TAmiRNA GmbH, 1110 Vienna, Austria.
  • Weigl M; TAmiRNA GmbH, 1110 Vienna, Austria.
  • Pultar M; TAmiRNA GmbH, 1110 Vienna, Austria.
  • Krammer TL; TAmiRNA GmbH, 1110 Vienna, Austria.
  • Fournier CA; Functional Genomics Center Zurich, ETH Zurich/University of Zurich, 8057 Zurich, Switzerland.
  • Schofield AL; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool L69 3GE, UK.
  • Otto C; Department of Neurology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
  • Smith AT; Lilly Research Laboratories, Department of Investigative Toxicology, Non Clinical Safety Assessment and Pathology, Lilly Corporate Center, Indianapolis, IN 46285, USA.
  • Buchtele N; Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria.
  • Schoergenhofer C; Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria.
  • Jilma B; Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria.
  • Frank BJH; Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria.
  • Hofstaetter JG; Michael Ogon Laboratory for Orthopaedic Research, Orthopaedic Hospital Vienna-Speising, 1130 Vienna, Austria.
  • Grillari R; Michael Ogon Laboratory for Orthopaedic Research, Orthopaedic Hospital Vienna-Speising, 1130 Vienna, Austria.
  • Grillari J; 2nd Department, Orthopaedic Hospital Vienna-Speising, 1130 Vienna, Austria.
  • Ruprecht K; Institute of Molecular Biotechnology, University of Natural Resources and Life Sciences, 1190 Vienna, Austria.
  • Goldring CE; Evercyte GmbH, 1110 Vienna, Austria.
  • Rehrauer H; Austrian Cluster for Tissue Regeneration, 1200 Vienna, Austria.
  • Glaab WE; Institute of Molecular Biotechnology, University of Natural Resources and Life Sciences, 1190 Vienna, Austria.
  • Hackl M; Austrian Cluster for Tissue Regeneration, 1200 Vienna, Austria.
Int J Mol Sci ; 23(3)2022 Jan 22.
Article em En | MEDLINE | ID: mdl-35163149
ABSTRACT
The plasma levels of tissue-specific microRNAs can be used as diagnostic, disease severity and prognostic biomarkers for chronic and acute diseases and drug-induced injury. Thereby, the combination of diverse microRNAs into biomarker signatures using multivariate statistics seems especially powerful from the perspective of tissue and condition specific microRNA shedding into the plasma. Although next-generation sequencing (NGS) technology enables one to analyse circulating microRNAs on a genome-scale level, it suffers from potential biases (e.g., adapter ligation bias) and lacks absolute transcript quantitation as well as tailor-made quality controls. In order to develop a robust NGS discovery assay for genome-scale quantitation of circulating microRNAs, we first evaluated the sensitivity, repeatability and ligation bias of four commercially available small RNA library preparation protocols. The protocol from RealSeq Biosciences was selected based on its performance and usability and coupled with a novel panel of exogenous small RNA spike-in controls to enable quality control and absolute quantitation, thus ensuring comparability of data across independent NGS experiments. The established microRNA Next-Generation-Sequencing Discovery Assay (miND) was validated for its relative accuracy, precision, analytical measurement range and sequencing bias and was considered fit-for-purpose for microRNA biomarker discovery. Summarized, all these criteria were met, and thus, our analytical platform is considered fit-for-purpose for microRNA biomarker discovery from biofluids in the setting of any diagnostic, prognostic or patient stratification need. The established miND assay was tested on serum, cerebrospinal fluid (CSF), synovial fluid (SF) and extracellular vesicles (EV) extracted from cell culture medium of primary cells and proved its potential to be used across different sample types.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores / Genoma Humano / Análise de Sequência de RNA / Sequenciamento de Nucleotídeos em Larga Escala / Vesículas Extracelulares / MicroRNA Circulante Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Áustria País de publicação: CH / SUIZA / SUÍÇA / SWITZERLAND

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores / Genoma Humano / Análise de Sequência de RNA / Sequenciamento de Nucleotídeos em Larga Escala / Vesículas Extracelulares / MicroRNA Circulante Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Áustria País de publicação: CH / SUIZA / SUÍÇA / SWITZERLAND